Pharmaceutical approaches to weight management: behavioural mechanisms of action

Roberts, Carl A ORCID: 0000-0003-4275-601X, Christiansen, Paul and Halford, Jason CG ORCID: 0000-0003-1629-3189 (2019) Pharmaceutical approaches to weight management: behavioural mechanisms of action. CURRENT OPINION IN PHYSIOLOGY, 12. pp. 26-32.

Text
1-s2.0-S2468867319300707-main.pdf - Author Accepted Manuscript
Download (483kB) | Preview

Official URL: http://dx.doi.org/10.1016/j.cophys.2019.04.017

Abstract

Pharmacotherapy as an adjunct to behaviour modification, may provide an effective addition to individual weight management plans in specialised weight management services. There are four FDA approved centrally acting weight-loss drugs (liraglutide, bupropion/naltrexone, lorcaserin, phentermine/topiramate), and several additional candidate drugs yet to receive approval. Each drug has a distinct pharmacological mechanism of action, and presumably will support eating behaviour modification in different ways. Here, we assess to what extent behavioural mechanisms of action have been characterised. We recommend a methodological platform to be introduced pre-approval in order to achieve principal objectives of phase II and III trials (demonstrate efficacy), and afford stratification of responders to treatment, by behavioural and neurophysiological response.

Item Type:	Article
Uncontrolled Keywords:	Clinical Trials and Supportive Activities, Clinical Research, Nutrition, Patient Safety, 5 Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, 6 Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals
Depositing User:	Symplectic Admin
Date Deposited:	24 May 2019 11:56
Last Modified:	15 Mar 2024 06:46
DOI:	10.1016/j.cophys.2019.04.017
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3042783